INmune Bio Partners With Quantum Computing Inc. to Advance Alzheimer's Drug Research
INmune Bio Inc. (INMB) and Quantum Computing Inc. (QUBT) have partnered to use quantum computing, artificial intelligence, and data analytics to evaluate new therapeutic uses for XPro, INmune Bio's investigational Alzheimer's disease drug. The project will analyze clinical and pre-clinical research data from four clinical trials alongside public biomedical datasets using Quantum Computing's Dirac-3S entropy quantum optimization machine.
The agreement represents Quantum Computing's first commercial customer in the pharmaceutical and biotechnology sector. By combining quantum optimization with conventional analytics, the companies aim to pinpoint patient populations and diseases driven by the same inflammation biology targeted by XPro, which selectively inhibits soluble tumor necrosis factor. The initial focus will center on rare diseases where clinical trials can be smaller and faster.
As part of the Stage 1 agreement, the companies plan to benchmark the quantum optimization results directly against traditional statistical and machine-learning models to determine where quantum technology adds distinct value. The deal also includes options for additional work as INmune Bio advances its clinical development programs.
Key points
- INmune Bio Inc. (INMB) and Quantum Computing Inc. (QUBT) partnered to apply quantum computing and AI to Alzheimer's candidate XPro.
- The collaboration marks Quantum Computing Inc.'s first commercial customer in the pharmaceutical and biotech industry.
- The project will use QCi's Dirac-3S quantum optimization machine to analyze data from four clinical trials and public datasets.
- Researchers will compare quantum optimization outcomes against conventional statistical and machine-learning methods.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What is the goal of the partnership between INmune Bio and Quantum Computing Inc.?
The companies are combining quantum computing, AI, and data analytics to analyze clinical trial data and identify new disease applications for INmune Bio's Alzheimer's treatment, XPro.
Why is this agreement significant for Quantum Computing Inc.?
The Stage 1 engagement represents Quantum Computing Inc.'s first commercial customer in the pharmaceutical and biotechnology market.
How will the companies evaluate the effectiveness of quantum computing in this study?
The companies will compare results from Quantum Computing's Dirac-3S quantum machine directly against conventional statistical and machine-learning methods.